Vertex Pharmaceuticals

Vertex Pharmaceuticals is one of the...

• Forbes Global 2000 (#619);
• Fortune 500 (#427);
• Nasdaq 100;
• Russell 3000;
• S&P 500.

Vertex Pharmaceuticals is a company listed under the stock ticker VRTX (US).

Vertex Pharmaceuticals has a direct presence in 2 countries.

They are in:

• Biotechnology67%
• Pharmaceuticals33%

Acquisition, funding and merger involving Vertex Pharmaceuticals.

• Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences  (posted on April 16 2024).
• Vertex Pharmaceuticals has announced the acquisition of ViaCyte  (posted on July 13 2022).

View the org chart displaying its 65 main executives

Most searched biographies at Vertex Pharmaceuticals

• Reshma Kewalramani, Director, President and Chief Executive Officer
• Sangeeta Bhatia, Director
• Jeffrey Leiden, Executive Chairman of the Board

Popular executive movements at Vertex Pharmaceuticals

• Nancy Thornberry has joined the company as Director  (posted on December 6 2023).
• Michel Lagarde has joined the company as Director  (posted on October 6 2023).
• Morrey Atkinson, who was Senior Vice Presiden and Head of Commercial Manufacturing & Supply Chain, is promoted to Executive Vice President, Chief Technical Operations Officer and Head of Biopharmaceutical Sciences & Manufacturing Operations  (posted on August 30 2023).

Create your alert
to follow the executive moves at Vertex Pharmaceuticals.

Vertex Pharmaceuticals has 2,282 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Endeavor BioMedicines has just announced a $132 Million fundraising (posted on April 25 2024).
• Metsera has just announced a $290 Million fundraising (posted on April 23 2024).
• Histogen has filed for bankruptcy protection  (posted on April 19 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion
• Vik Bajaj - Director at Interline Therapeutics

Learn more about the Biotechnology industry >

Press releases by Vertex Pharmaceuticals

• Press Releases | Vertex Pharmaceuticals Newsroom
• Vertex Advances VX-548 in Acute and Neuropathic Pain | Vertex Pharmaceuticals Newsroom
• Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease | Vertex Pharmaceuticals Newsroom
• Vertex to Announce Second Quarter 2022 Financial Results on August 4 | Vertex Pharmaceuticals Newsroom
• Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
• Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
• Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Newsroom
• Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference | Vertex Newsroom
• Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 | Vertex Newsroom
• Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA | Vertex Newsroom
• View more press releases Close

Social media about Vertex Pharmaceuticals

• Vertex Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Vertex Pharmaceuticals on LinkedIn, Twitter & YouTube

Contact by email its executives including Reshma Kewalramani

Call Vertex Pharmaceuticals at +1 617...

View the org chart

Register to receive your alert

Report an error